Dendreon CEO resigns

Share this article:

Dendreon CEO John Johnson is calling it quits. The Seattle manufacturer of prostate cancer drug Provenge announced Monday that Johnson was leaving for personal reasons. Douglas Watson has replaced Johnson as chairman of the board. Johnson will remain president and CEO through August 15.

The Street's Adam Feuerstein noted Monday that Johnson is leaving the beleaguered company as it is subsumed by debt, and says the company will make its June $28 million payment, but “has no means to pay the $560 million in debt due in 2016.”

Johnson was named CEO in February 2013.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.